<?xml version="1.0" encoding="UTF-8"?>
<p id="par0310">CYNK-001 (intravenous infusion of natural killer (NK) cells) is the name of yet another trial that has enrolled COVID-19 patients. It aims to boost immune systems of patients at risk of more severe disease and those starting to show symptoms by applying CYNK-001. The mechanism has been slowing virus replication [
 <xref rid="bib0450" ref-type="bibr">90</xref>].
</p>
